What is the P/E ratio of Cell Impact AB (publ) 2024?
The Cell Impact AB (publ) P/E ratio is -1.67.
The Quote Chart provides detailed and dynamic insights into the Cell Impact AB (publ) stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
The intraday feature provides real-time data, allowing investors to view the Cell Impact AB (publ) stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
View the total return of the Cell Impact AB (publ) stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Utilize the comprehensive data presented in the Quote Chart to analyze Cell Impact AB (publ)'s market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Date | Cell Impact AB (publ) Price |
---|---|
9/6/2024 | 0.24 SEK |
9/5/2024 | 0.25 SEK |
9/4/2024 | 0.26 SEK |
9/3/2024 | 0.27 SEK |
9/2/2024 | 0.24 SEK |
8/30/2024 | 0.23 SEK |
8/29/2024 | 0.24 SEK |
8/28/2024 | 0.25 SEK |
8/27/2024 | 0.26 SEK |
8/26/2024 | 0.27 SEK |
8/23/2024 | 0.29 SEK |
8/22/2024 | 0.29 SEK |
8/21/2024 | 0.30 SEK |
8/20/2024 | 0.31 SEK |
8/19/2024 | 0.32 SEK |
8/16/2024 | 0.32 SEK |
8/15/2024 | 0.31 SEK |
8/14/2024 | 0.29 SEK |
8/13/2024 | 0.30 SEK |
8/12/2024 | 0.30 SEK |
3 years
5 years
10 years
25 Years
Max
Gain insights into Cell Impact AB (publ), a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cell Impact AB (publ) from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cell Impact AB (publ)’s net earnings, an ultimate measure of its financial health and profitability.
Observe the yearly bars to understand the annual performance and growth of Cell Impact AB (publ). Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
The expected values for the forthcoming years offer investors a glimpse into Cell Impact AB (publ)’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Leveraging the comparison between Revenue and EBIT helps in assessing Cell Impact AB (publ)’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cell Impact AB (publ)’s growth potential.
Date | Cell Impact AB (publ) Revenue | Cell Impact AB (publ) EBIT | Cell Impact AB (publ) Net Income |
---|---|---|---|
2025e | 175.1 M SEK | -51.5 M SEK | -54.83 M SEK |
2024e | 92.7 M SEK | -85.49 M SEK | -85.29 M SEK |
2023 | 47.26 M SEK | -119.49 M SEK | -121.4 M SEK |
2022 | 76.81 M SEK | -103.47 M SEK | -104.22 M SEK |
2021 | 81.8 M SEK | -78.04 M SEK | -79.85 M SEK |
2020 | 29.31 M SEK | -43.06 M SEK | -44.26 M SEK |
2019 | 12 M SEK | -47.44 M SEK | -48.4 M SEK |
2018 | 6.82 M SEK | -44.4 M SEK | -44.57 M SEK |
2017 | 1.74 M SEK | -18.04 M SEK | -18.29 M SEK |
2016 | 1.88 M SEK | -8.36 M SEK | -8.58 M SEK |
2015 | 1.93 M SEK | -7.34 M SEK | -7.35 M SEK |
2014 | 3.7 M SEK | -7.78 M SEK | -7.75 M SEK |
2013 | 3.43 M SEK | -7.63 M SEK | -7.6 M SEK |
2012 | 1.36 M SEK | -8.05 M SEK | -8.12 M SEK |
2011 | 1.86 M SEK | -15.32 M SEK | -14.93 M SEK |
2010 | 30,000 SEK | -430,000 SEK | -420,000 SEK |
Revenue | EBIT | Net Income | |
---|---|---|---|
2010 | 30,000 SEK | -430,000 SEK | -420,000 SEK |
2011 | 1.86 M SEK | -15.32 M SEK | -14.93 M SEK |
2012 | 1.36 M SEK | -8.05 M SEK | -8.12 M SEK |
2013 | 3.43 M SEK | -7.63 M SEK | -7.6 M SEK |
2014 | 3.7 M SEK | -7.78 M SEK | -7.75 M SEK |
2015 | 1.93 M SEK | -7.34 M SEK | -7.35 M SEK |
2016 | 1.88 M SEK | -8.36 M SEK | -8.58 M SEK |
2017 | 1.74 M SEK | -18.04 M SEK | -18.29 M SEK |
2018 | 6.82 M SEK | -44.4 M SEK | -44.57 M SEK |
2019 | 12 M SEK | -47.44 M SEK | -48.4 M SEK |
2020 | 29.31 M SEK | -43.06 M SEK | -44.26 M SEK |
2021 | 81.8 M SEK | -78.04 M SEK | -79.85 M SEK |
2022 | 76.81 M SEK | -103.47 M SEK | -104.22 M SEK |
2023 | 47.26 M SEK | -119.49 M SEK | -121.4 M SEK |
2024e | 92.7 M SEK | -85.49 M SEK | -85.29 M SEK |
2025e | 175.1 M SEK | -51.5 M SEK | -54.83 M SEK |
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 1 | 3 | 3 | 1 | 1 | 1 | 6 | 12 | 29 | 81 | 76 | 47 | 92 | 175 |
- | - | - | 200.00 | - | -66.67 | - | - | 500.00 | 100.00 | 141.67 | 179.31 | -6.17 | -38.16 | 95.74 | 90.22 |
- | 100.00 | 100.00 | 66.67 | 66.67 | 100.00 | - | - | -100.00 | 25.00 | 65.52 | 41.98 | -6.58 | -29.79 | - | - |
0 | 1 | 1 | 2 | 2 | 1 | 0 | 0 | -6 | 3 | 19 | 34 | -5 | -14 | 0 | 0 |
0 | -15 | -8 | -7 | -7 | -7 | -8 | -18 | -44 | -47 | -43 | -78 | -103 | -119 | -85 | -51 |
- | -1,500.00 | -800.00 | -233.33 | -233.33 | -700.00 | -800.00 | -1,800.00 | -733.33 | -391.67 | -148.28 | -96.30 | -135.53 | -253.19 | -92.39 | -29.14 |
0 | -14 | -8 | -7 | -7 | -7 | -8 | -18 | -44 | -48 | -44 | -79 | -104 | -121 | -85 | -54 |
- | - | -42.86 | -12.50 | - | - | 14.29 | 125.00 | 144.44 | 9.09 | -8.33 | 79.55 | 31.65 | 16.35 | -29.75 | -36.47 |
8.92 | 8.92 | 8.97 | 10.99 | 15.82 | 15.82 | 15.01 | 22.12 | 26.82 | 48.51 | 53.72 | 59.21 | 238.98 | 591.45 | 0 | 0 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
The Cell Impact AB (publ) Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cell Impact AB (publ) is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
3 years
5 years
10 years
25 Years
Max
The gross margin, expressed as a percentage, delineates the gross profit made from the Cell Impact AB (publ)'s sales revenue. A higher gross margin percentage indicates that the Cell Impact AB (publ) retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT margin represents the Cell Impact AB (publ)'s earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
The revenue margin demonstrates the Cell Impact AB (publ)'s total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cell Impact AB (publ)'s growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cell Impact AB (publ). Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cell Impact AB (publ)'s financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Cell Impact AB (publ) Gross margin | Cell Impact AB (publ) Profit margin | Cell Impact AB (publ) EBIT margin | Cell Impact AB (publ) Profit margin |
---|---|---|---|
2025e | -30.13 % | -29.41 % | -31.31 % |
2024e | -30.13 % | -92.22 % | -92 % |
2023 | -30.13 % | -252.83 % | -256.88 % |
2022 | -7.27 % | -134.7 % | -135.68 % |
2021 | 42.64 % | -95.4 % | -97.62 % |
2020 | 65.3 % | -146.91 % | -151.01 % |
2019 | 26.83 % | -395.33 % | -403.33 % |
2018 | -98.39 % | -651.03 % | -653.52 % |
2017 | 43.1 % | -1,036.78 % | -1,051.15 % |
2016 | 38.3 % | -444.68 % | -456.38 % |
2015 | 79.79 % | -380.31 % | -380.83 % |
2014 | 72.7 % | -210.27 % | -209.46 % |
2013 | 65.31 % | -222.45 % | -221.57 % |
2012 | 73.53 % | -591.91 % | -597.06 % |
2011 | 55.38 % | -823.66 % | -802.69 % |
2010 | 166.67 % | -1,433.33 % | -1,400 % |
Gross margin | EBIT margin | Profit margin | |
---|---|---|---|
2010 | 166.67 % | -1,433.33 % | -1,400 % |
2011 | 55.38 % | -823.66 % | -802.69 % |
2012 | 73.53 % | -591.91 % | -597.06 % |
2013 | 65.31 % | -222.45 % | -221.57 % |
2014 | 72.7 % | -210.27 % | -209.46 % |
2015 | 79.79 % | -380.31 % | -380.83 % |
2016 | 38.3 % | -444.68 % | -456.38 % |
2017 | 43.1 % | -1,036.78 % | -1,051.15 % |
2018 | -98.39 % | -651.03 % | -653.52 % |
2019 | 26.83 % | -395.33 % | -403.33 % |
2020 | 65.3 % | -146.91 % | -151.01 % |
2021 | 42.64 % | -95.4 % | -97.62 % |
2022 | -7.27 % | -134.7 % | -135.68 % |
2023 | -30.13 % | -252.83 % | -256.88 % |
2024e | -30.13 % | -92.22 % | -92 % |
2025e | -30.13 % | -29.41 % | -31.31 % |
3 years
5 years
10 years
25 Years
Max
Revenue per share represents the total revenue Cell Impact AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Cell Impact AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Cell Impact AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cell Impact AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Date | Cell Impact AB (publ) Sales per Share | Cell Impact AB (publ) EBIT per share | Cell Impact AB (publ) Earnings per Share |
---|---|---|---|
2025e | 0.3 SEK | 0 SEK | -0.09 SEK |
2024e | 0.16 SEK | 0 SEK | -0.14 SEK |
2023 | 0.08 SEK | -0.2 SEK | -0.21 SEK |
2022 | 0.32 SEK | -0.43 SEK | -0.44 SEK |
2021 | 1.38 SEK | -1.32 SEK | -1.35 SEK |
2020 | 0.55 SEK | -0.8 SEK | -0.82 SEK |
2019 | 0.25 SEK | -0.98 SEK | -1 SEK |
2018 | 0.25 SEK | -1.66 SEK | -1.66 SEK |
2017 | 0.08 SEK | -0.82 SEK | -0.83 SEK |
2016 | 0.13 SEK | -0.56 SEK | -0.57 SEK |
2015 | 0.12 SEK | -0.46 SEK | -0.46 SEK |
2014 | 0.23 SEK | -0.49 SEK | -0.49 SEK |
2013 | 0.31 SEK | -0.69 SEK | -0.69 SEK |
2012 | 0.15 SEK | -0.9 SEK | -0.91 SEK |
2011 | 0.21 SEK | -1.72 SEK | -1.67 SEK |
2010 | 0 SEK | -0.05 SEK | -0.05 SEK |
Sales per Share | EBIT per share | Earnings per Share | |
---|---|---|---|
2010 | 0 SEK | -0.05 SEK | -0.05 SEK |
2011 | 0.21 SEK | -1.72 SEK | -1.67 SEK |
2012 | 0.15 SEK | -0.9 SEK | -0.91 SEK |
2013 | 0.31 SEK | -0.69 SEK | -0.69 SEK |
2014 | 0.23 SEK | -0.49 SEK | -0.49 SEK |
2015 | 0.12 SEK | -0.46 SEK | -0.46 SEK |
2016 | 0.13 SEK | -0.56 SEK | -0.57 SEK |
2017 | 0.08 SEK | -0.82 SEK | -0.83 SEK |
2018 | 0.25 SEK | -1.66 SEK | -1.66 SEK |
2019 | 0.25 SEK | -0.98 SEK | -1 SEK |
2020 | 0.55 SEK | -0.8 SEK | -0.82 SEK |
2021 | 1.38 SEK | -1.32 SEK | -1.35 SEK |
2022 | 0.32 SEK | -0.43 SEK | -0.44 SEK |
2023 | 0.08 SEK | -0.2 SEK | -0.21 SEK |
2024e | 0.16 SEK | 0 SEK | -0.14 SEK |
2025e | 0.3 SEK | 0 SEK | -0.09 SEK |
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
3 years
5 years
10 years
25 Years
Max
Revenue per share represents the total revenue Cell Impact AB (publ) earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates Cell Impact AB (publ)'s earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of Cell Impact AB (publ)’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cell Impact AB (publ)'s prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Number of stocks | |
---|---|
2010 | 8.92 M Aktien |
2011 | 8.92 M Aktien |
2012 | 8.97 M Aktien |
2013 | 10.99 M Aktien |
2014 | 15.82 M Aktien |
2015 | 15.82 M Aktien |
2016 | 15.01 M Aktien |
2017 | 22.12 M Aktien |
2018 | 26.82 M Aktien |
2019 | 48.51 M Aktien |
2020 | 53.72 M Aktien |
2021 | 59.21 M Aktien |
2022 | 238.98 M Aktien |
2023 | 591.45 M Aktien |
2024e | 591.45 M Aktien |
2025e | 591.45 M Aktien |
% | Name | Stocks | Change | Date |
---|---|---|---|---|
7.01713 % | Avanza Bank Holding AB | 41,502,794 | 36,691,600 | 12/27/2023 |
5.86047 % | Östersjöstiftelsen | 34,661,763 | 30,810,456 | 12/27/2023 |
5.59203 % | Nordnet Pensionsforsakring AB | 33,074,032 | 32,104,875 | 12/27/2023 |
1.94451 % | Exelity AB (publ) | 11,500,816 | 11,500,816 | 12/27/2023 |
1.82741 % | Movestic Livsförsäkring AB | 10,808,200 | 10,808,200 | 12/27/2023 |
1.63327 % | Larsson (Lennart) | 9,660,000 | 8,645,000 | 12/27/2023 |
1.09054 % | Ismail (Arian) | 6,450,000 | 6,450,000 | 12/27/2023 |
0.84538 % | Aleksov (Oliver) | 5,000,000 | 5,000,000 | 12/27/2023 |
0.21814 % | Grünes Geld Vermögensmanagement GmbH | 1,290,169 | -457,545 | 12/27/2023 |
0.05874 % | Storebrand Kapitalforvaltning AS | 347,445 | 0 | 2/29/2024 |
The Cell Impact AB (publ) P/E ratio is -1.67.
The Cell Impact AB (publ) P/S ratio is 1.54.
The AlleAktien quality score for Cell Impact AB (publ) is 7/10.
The expected Cell Impact AB (publ) revenue is 92.7 M SEK.
The expected Cell Impact AB (publ) profit is -85.29 M SEK.
No history available for Cell Impact AB (publ).
Cell Impact AB (publ) pays a dividend of 0 SEK distributed over payouts per year.
The dividend cannot currently be calculated for Cell Impact AB (publ) or the company does not pay out a dividend.
The ISIN of Cell Impact AB (publ) is SE0017885379.
The WKN of Cell Impact AB (publ) is A3DL44.
The ticker of Cell Impact AB (publ) is CI.ST.
Over the past 12 months, Cell Impact AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cell Impact AB (publ) is expected to pay a dividend of 0 SEK.
The current dividend yield of Cell Impact AB (publ) is .
Cell Impact AB (publ) pays a quarterly dividend. This is distributed in the months of .
Cell Impact AB (publ) paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
Cell Impact AB (publ) is assigned to the 'Industry' sector.
To receive the latest dividend of Cell Impact AB (publ) from 9/9/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.
The last dividend was paid out on 9/9/2024.
In the year 2023, Cell Impact AB (publ) distributed 0 SEK as dividends.
The dividends of Cell Impact AB (publ) are distributed in SEK.
Stock Exchange | Cell Impact AB (publ) Ticker |
---|---|
DÜSSELDORF | ICLA.DU |
FRANKFURT | ICLA.F |
HAMBURG | ICLA.HM |
MUNICH | ICLA.MU |
STOCKHOLM | CI.ST |
STOCKHOLM | CI.ST |
Cell Impact AB (publ) Ticker | Cell Impact AB (publ) FIGI |
---|---|
CI:SF | BBG0045CC9L3 |
ICLA:GR | BBG00474DS36 |
ICLA:GF | BBG00474DS45 |
ICLA:GD | BBG00474DS54 |
ICLA:GS | BBG00474DS72 |
ICLA:GM | BBG00474DS81 |
ICLA:GB | BBG00474DS90 |
ICLA:GI | BBG00474DSC6 |
ICLA:GH | BBG00474DSD5 |
CIBSEK:XH | BBG0058MDY66 |
CIBSEK:XF | BBG0058MDY84 |
CIBSEK:XE | BBG0058MDYB0 |
CIBSEK:XL | BBG0058MDYD8 |
CIBSEK:XG | BBG0058MDYF6 |
CIBSEK:XO | BBG0058MDYG5 |
CIBSEK:XA | BBG0058MDYM8 |
CIBSEK:XT | BBG0058MDYP5 |
CIBSEK:XW | BBG0058MDYQ4 |
CIBSEK:XU | BBG0058MDYR3 |
CIBSEK:EU | BBG0058MDYV8 |
CIBSEK:XV | BBG005925T69 |
CIS:PO | BBG00JL6ZTJ9 |
CIS:B3 | BBG00JLWQM61 |
CIS:L3 | BBG00JLXCF32 |
CIB1EUR:XH | BBG00JWVSM32 |
CIB1EUR:XF | BBG00JWVSM50 |
CIB1EUR:XE | BBG00JWVSM78 |
CIB1EUR:XL | BBG00JWVSM96 |
CIB1EUR:XG | BBG00JWVSMB3 |
CIB1EUR:XO | BBG00JWVSMC2 |
CIB1EUR:XA | BBG00JWVSMJ5 |
CIB1EUR:XT | BBG00JWVSML2 |
CIB1EUR:XW | BBG00JWVSMM1 |
CIB1EUR:XU | BBG00JWVSMN0 |
CIB1EUR:XV | BBG00JWVSMP8 |
CIB1EUR:XM | BBG00JWVSMQ7 |
CIB1EUR:EU | BBG00JWVSMX9 |
ICLA:TH | BBG00RHDR1R2 |
ICLA:GZ | BBG00RN6T1P0 |
CIB1GBP:X2 | BBG00S9SSS23 |
CIB1GBP:XH | BBG00S9SSS41 |
CIB1GBP:XF | BBG00S9SSS69 |
CIB1GBP:XE | BBG00S9SSS87 |
CIB1GBP:XL | BBG00S9SSSB3 |
CIB1GBP:XG | BBG00S9SSSC2 |
CIB1GBP:XO | BBG00S9SSSD1 |
CIB1GBP:XA | BBG00S9SSSJ5 |
CIB1GBP:XT | BBG00S9SSSL2 |
CIB1GBP:XW | BBG00S9SSSM1 |
CIB1GBP:XU | BBG00S9SSSN0 |
CIB1GBP:XV | BBG00S9SSSQ7 |
CIB1GBP:XM | BBG00S9SSSR6 |
CIB1GBP:X1 | BBG00S9SSSX9 |
CIB1GBP:EU | BBG00S9SSSZ7 |
ICLA:QT | BBG00WVQWKR8 |
CIS:L1 | BBG00Y7BMP94 |
ICLA:LA | BBG018H98LF2 |
ICLA:LU | BBG018J2XM74 |
Our stock analysis for Cell Impact AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cell Impact AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.